文献速递儿科影像技术与安全MRPET

儿童肿瘤治疗反应评估:全身扩散加权MRI与FDG PET/MRI对比

Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI.
PubMed 文献 · Radiology · 2020-05-05

前瞻性非随机多中心研究纳入56例淋巴瘤或肉瘤儿童及年轻患者,于诱导化疗前后行112次全身扩散加权MRI与FDG PET/MRI同步检查;两种方法治疗反应评估一致性良好(Krippendorff α=0.88),最大SUV与最小ADC预测临床反应的AUC相似(100% vs 98%,P=0.37)。

要点

  • 全身扩散加权MRI与FDG PET/MRI对儿童淋巴瘤或肉瘤诱导化疗后反应评估一致性良好(α=0.88)。
  • 最大SUV预测临床反应AUC为100%(95%CI 99%,100%),最小ADC为98%(95%CI 94%,100%),两者相似(P=0.37)。
  • 8/56例诱导化疗后早期成像患者中,肿瘤代谢变化先于质子扩散变化(P=0.002)。

核心结论

  • 全身扩散加权MRI与氟18氟脱氧葡萄糖PET/MRI在儿童及年轻患者治疗反应评估中显示显著一致性。

研究设计与样本

  • 前瞻性非随机多中心研究,纳入56例淋巴瘤或肉瘤儿童及年轻患者(31男25女,平均年龄15岁±4,范围6-22岁)。
  • 2015年6月至2018年12月间于诱导化疗前后行112次同步全身扩散加权MRI与FDG PET/MRI(ClinicalTrials.gov标识NCT01542879)。
  • 测量最多6个靶病灶的最小肿瘤表观扩散系数(ADC)和最大标准化摄取值(SUV),按Lugano分类或实体瘤PET反应标准评估诱导化疗后治疗反应。

诊断标准与关键数值

  • 全身扩散加权MRI与FDG PET/MRI治疗反应分类一致性Krippendorff α=0.88。
  • 最大SUV预测临床反应AUC=100%(95%CI 99%,100%),最小ADC预测临床反应AUC=98%(95%CI 94%,100%),两者相似(P=0.37)。
  • 扩散加权MRI敏感度96%(54/56,95%CI 86%,99%)、特异度100%(56/56,95%CI 54%,100%)。
  • FDG PET/MRI敏感度100%(56/56,95%CI 93%,100%)、特异度100%(56/56,95%CI 54%,100%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Whole-body diffusion-weighted (DW) MRI can help detect cancer with high sensitivity. However, the assessment of therapy response often requires information about tumor metabolism, which is measured with fluorine 18 fluorodeoxyglucose (FDG) PET. Purpose To compare tumor therapy response with whole-body DW MRI and FDG PET/MRI in children and young adults. Materials and Methods In this prospective, nonrandomized multicenter study, 56 children and young adults (31 male and 25 female participants; mean age, 15 years ± 4 [standard deviation]; age range, 6-22 years) with lymphoma or sarcoma underwent 112 simultaneous whole-body DW MRI and FDG PET/MRI between June 2015 and December 2018 before and after induction chemotherapy (ClinicalTrials.gov identifier: NCT01542879). The authors measured minimum tumor apparent diffusion coefficients (ADCs) and maximum standardized uptake value (SUV) of up to six target lesions and assessed therapy response after induction chemotherapy according to the Lugano classification or PET Response Criteria in Solid Tumors. The authors evaluated agreements between whole-body DW MRI- and FDG PET/MRI-based response classifications with Krippendorff α statistics. Differences in minimum ADC and maximum SUV between responders and nonresponders and comparison of timing for discordant and concordant response assessments after induction chemotherapy were evaluated with the Wilcoxon test. Results Good agreement existed between treatment response assessments after induction chemotherapy with whole-body DW MRI and FDG PET/MRI (α = 0.88). Clinical response prediction according to maximum SUV (area under the receiver operating characteristic curve = 100%; 95% confidence interval [CI]: 99%, 100%) and minimum ADC (area under the receiver operating characteristic curve = 98%; 95% CI: 94%, 100%) were similar (P = .37). Sensitivity and specificity were 96% (54 of 56 participants; 95% CI: 86%, 99%) and 100% (56 of 56 participants; 95% CI: 54%, 100%), respectively, for DW MRI and 100% (56 of 56 participants; 95% CI: 93%, 100%) and 100% (56 of 56 participants; 95% CI: 54%, 100%) for FDG PET/MRI. In eight of 56 patients who underwent imaging after induction chemotherapy in the early posttreatment phase, chemotherapy-induced changes in tumor metabolism preceded changes in proton diffusion (P = .002). Conclusion Whole-body diffusion-weighted MRI showed significant agreement with fluorine 18 fluorodeoxyglucose PET/MRI for treatment response assessment in children and young adults. © RSNA, 2020 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Theruvath AJ, Siedek F, Muehe AM, et al. Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI. Radiology. 2020. PMID: 32368961. doi:10.1148/radiol.2020192508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。